Tango Therapeutics, a biotechnology company specializing in cancer treatments, has taken significant measures to address the challenging financial landscape. Recently, the company announced layoffs affecting approximately 20% of its workforce, a strategic move designed to extend its cash runway. As
The biopharmaceutical sector has witnessed significant changes in leadership roles within major Contract Development and Manufacturing Organizations (CDMOs), driving strategic growth and development. The appointment of seasoned leaders plays a crucial role in strengthening the research,
Artis Biosolutions' acquisition of Landmark Bio marks a strategic move designed to bolster cell and gene therapy (CGT) manufacturing capabilities. Landmark Bio, founded by Harvard University, MIT, Fujifilm Diosynth Biotechnologies, Alexandria Real Estate Equities, and Cytiva, has been a key player
The COVID-19 pandemic underscored significant challenges that tested the resilience of the global biotech industry, causing unprecedented disruptions but also highlighting areas ripe for growth and innovation. Against this backdrop, the Gulf Cooperation Council (GCC) countries, with Saudi Arabia at
Ivan Kairatov is a Biopharma expert, with deep knowledge of tech and innovation in the industry and experience in research and development. He joins us today to discuss Ori Biotech’s new Preferred Partner Network (PPN), the collaboration with various organizations, and the impacts on cell therapy
Ivan Kairatov is a Biopharma expert, with deep knowledge of tech and innovation in the industry and experience in research and development. Today, we will be discussing the Medicines Manufacturing Centre (MMC) project in the U.K., the increasing demand for monoclonal antibodies (mAbs) and advanced
